Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
Eur J Med Chem. 2013 Jul;65:315-22. doi: 10.1016/j.ejmech.2013.04.067. Epub 2013 May 13.
A new series of diarylureas and diarylamides possessing 1,3,4-triarylpyrazole scaffold was designed and synthesized. Their in vitro antiproliferative activities against NCI-60 cell line panel were tested. Most of the compounds showed strong and broad-spectrum antiproliferative activities. Compound 18 exerted sub-micromolar IC50 values over all the subpanels of nine different cancer types. Its IC50 value over MDA-MB-435 melanoma cell line was 27 nM. Compounds 10-13, 22, and 23 possessing urea spacer exerted lethal effect over the NCI-60 panel with mean %inhibitions more than 100% in single-dose testing. Compounds 13 and 23 with urea linker and 3',5'-bis(trifluoromethyl)phenyl terminal ring showed the highest mean %inhibition over the NCI-60 panel in single-dose testing, and showed high potencies and broad-spectrum anticancer activities in five-dose testing.
设计并合成了一系列具有 1,3,4-三芳基吡唑骨架的新型二芳基脲和二芳基酰胺。测试了它们对 NCI-60 细胞系谱的体外增殖活性。大多数化合物表现出强烈和广谱的增殖抑制活性。化合物 18 在九种不同癌症类型的所有亚组中均表现出亚微摩尔 IC50 值。其对 MDA-MB-435 黑色素瘤细胞系的 IC50 值为 27 nM。具有脲间隔基的化合物 10-13、22 和 23 在单剂量测试中对 NCI-60 谱表现出致死作用,平均抑制率超过 100%。具有脲连接基和 3',5'-双(三氟甲基)苯基末端环的化合物 13 和 23 在单剂量测试中对 NCI-60 谱的平均抑制率最高,在五剂量测试中表现出高活性和广谱抗癌活性。